Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Stéphane Zuily
- Target Recruit Count
- 500
- Registration Number
- NCT04262492
- Locations
- 🇫🇷
Stéphane Zuily, Nancy, France
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Drahomir Aujesky
- Target Recruit Count
- 276
- Registration Number
- NCT04263038
- Locations
- 🇧🇪
Centre hospitalier universitaire de Liege, Liège, Belgium
🇨🇦The Ottawa Hospital, Ottawa, Canada
🇫🇷CHU Gabriel-Montpied, Clermont-Ferrand, France
Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 826
- Registration Number
- NCT04135677
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan Univerisity, Shanghai, Shanghai, China
Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1200
- Registration Number
- NCT04096547
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-04-18
- Target Recruit Count
- 224
- Registration Number
- NCT04067505
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Shanghai 5th People's Hospital, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-04-18
- Target Recruit Count
- 200
- Registration Number
- NCT04066764
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, Shangdong, China
🇨🇳Shanghai 5th People's Hospital, Shanghai, Shanghai, China
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 90
- Registration Number
- NCT04006288
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
DOAC Versus VKA After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Laval University
- Registration Number
- NCT04002011
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 319
- Registration Number
- NCT03996772
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
🇩🇪University Hospital Schleswig-Holstein Campus Luebeck, Luebeck, Germany
🇩🇪Klinikum Altenburger Land, Altenburg, Germany
RIvoraxaban in Mitral Stenosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2021-08-19
- Target Recruit Count
- 40
- Registration Number
- NCT03926156
- Locations
- 🇮🇷
Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.